GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Guadecitabine (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 29 Nov 2017 Status changed from not yet recruiting to recruiting.
- 27 Nov 2017 Planned initiation date changed from 1 Nov 2017 to 1 Feb 2018.